chrisvoncsefalvay/vaers-outcomes huggingface dataset:
developed a rash that itches and burns on her hip, bursa and under her breast; developed a rash that itches and burns on her hip, bursa and under her breast; developed a rash that itches and burns on her hip, bursa and under her breast; pain/hurting; tired; lack of appetite; nausea; can hardly walk; This is a spontaneous report from a contactable consumer (patient's daughter).   A 78 year old female patient of an unspecified age received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration on 07May2021 (Batch/Lot number was not reported) as single dose  for covid-19 immunisation  .  Medical history included , fibromyalgia , herpes zoster (Had shingles 4 times before). On 16Apr2021 the patient received the first dose of BNT162B2 vaccine.     The patient's concomitant medications were not reported.  The patient  developed a rash that itches and burns on her hip, bursa and under her breast  on 09May2021 with outcome of unknown ,  pain/hurting  on 09May2021 with outcome of unknown , tired  on 09May2021 with outcome of unknown , lack of appetite  on 09May2021 with outcome of unknown , nausea on 09May2021 with outcome of unknown , can hardly walk  on 09May2021 with outcome of unknown.     No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Information has been received from a pharmacist concerning a 74 year old male patient who about one years ago (in 2009) was vaccinated with a dose of ZOSTAVAX (Merck). Subsequently, the patient currently had shingles from his right shoulder towards his ear. The patient was receiving VALTREX. The patient contacted a physician for medical attention. The case would be considered mild by the reporter. The patient was in good health. The patient and his sister in law were both vaccinated by the same physician (WAES# 1006USA00338). This is one of several reports received from the same source. Additional information has been requested.
Patient is 57 years old, and received the adjuvant flu shot rec for 65 years and older
Patient contracted COVID after being fully vaccinated - Cough, fatigue, sinus pressure, muscle aches.
9 days after the shot I woke to swelling, rash, bumps and itching at injection site. 12 days after the shot I'm experiencing itching in my fingers and welts appearing on my fingers and back.
Itchy splotches on upper part of face; Hurt if touched; Multiple itchy, touch sensitive dark spots on face size of a nickel; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itchy splotches on upper part of face), PAIN (Hurt if touched) and RASH (Multiple itchy, touch sensitive dark spots on face size of a nickel) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     Previously administered products included for an unreported indication: ZOSTER (The patient received first dose shingles vaccine.) on 03-Jan-2021. Concurrent medical conditions included Hypertension and Seasonal allergy.    On 25-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, the patient experienced PRURITUS (Itchy splotches on upper part of face), PAIN (Hurt if touched) and RASH (Multiple itchy, touch sensitive dark spots on face size of a nickel). At the time of the report, PRURITUS (Itchy splotches on upper part of face), PAIN (Hurt if touched) and RASH (Multiple itchy, touch sensitive dark spots on face size of a nickel) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication list include high blood pressure medication and inhaler for seasonal allergies. Treatment information was not provided.
Presented to COVID Vaccine Clinic with known history of allergic reaction to MSO4-stated it was anaphylactic in nature, happened while in the hospital. Approx 10 min after vaccine administration patient began to complain of being unable to swallow, unable to take a breath, unable to speak.  Treated with EpiPen x 1 with improvement.  Taken via EMS to local hospital where she was observed/monitored and discharged home.
2.5 inch wheal with pruritus localized to injection site of varicella within 24 hours after administering vaccine. No other s/sx of adverse reactions. TYLENOL prescribed, symptoms reduced 24 hours after administered.
pt vaccinated on 3/22/2021 tested positive for covid 19 on 7/28/2021 hospitalized in the icu on high flow oxygen.
After vaccination next day very sore, stiff for a day or so .  After second day profuse sweating  after doing almost anything for a week or so.  Since that it doesn't take a lot of physical activity to cause sweating. As of this date it seems to be a long term thing.  I used to use my exercise bike to go 6 miles with only some sweating this time of year. Now I put a fan on after the first mile so l don't sweat so much.  I also seem to have less energy to do things.
pt recv vax 24FEB97 & pt devel hives & erythema 1/2-2cm treated w/DPh;generalized on trunk only;
10 days after receiving my booster hives started forming all over my body.  I've taken antihistamines and prednisone, and the hives have lessened but I still have large rashes and itching all over my body.
Received 2nd Moderna dose 2/4/21. Reports cough, shortness of breath, fatigue, muscle aches, headache starting on 2/4, late night. Headache started very strong, but became low grade and persisting till 2/7. Team member suffers from asthma, but her condition has been under control for over 10 years, with Symbicort taken twice daily, and has not had an asthma attack for over 2 years. TM missed 2/5 from work. TM has been scheduled to test on 2/12.
Narrative:  89 year old male, received first dose of COVID-19 vaccine (Pfizer) on 2/11/2021. Contacted medicine team 3/11/2021 with complaint of a "bad reaction" and still recovering. Declined scheduled second dose (due 3/4/2021). No other updates from patient. Expired 3/15/2021.
Burning Skin Sensation started in lower back and moved up to shoulders and lower neck area both sides plus mild headache.
Skin: Rashes 3x2 cm erythema, warm around VZV site on right arm.
I received my second shot in my right arm, and my right jaw was painful, but not nearly as much. And no locked up jaw.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 31Mar2021 15:30 (Lot number: ER8734) at the age of 53 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "HBP controlled with medicine" (unspecified if ongoing); "slightly low thyroid" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Bnt162b2 (Product=COVID 19 , Brand= Pfizer, Lot number= EP6955, Lot unknown=False, Administration date=12Mar2021, Administration time=10:30 AM, Vaccine location=Left arm , Dose number=1), administration date: 12Mar2021, when the patient was 53 years old, for Covid-19 Immunisation. The following information was reported: PAIN IN JAW (non-serious) with onset 2021, outcome "recovered" (2021), described as "I received my second shot in my right arm, and my right jaw was painful, but not nearly as much. And no locked up jaw.". The event "i received my second shot in my right arm, and my right jaw was painful, but not nearly as much. and no locked up jaw." was evaluated at the physician office visit. Therapeutic measures were not taken as a result of pain in jaw.  Additional information: Patient received his second shot in his right arm and right jaw was painful, but not nearly as much. And no locked up jaw. Patient talked to dentist and he did not know if it was related or not. Just wanted to make sure he passed this along. No covid prior vaccination and covid tested post vaccination. No other vaccine in four weeks and patient took unknown other medications in two weeks.  No follow-up attempts are possible. No further information is expected.
received the first two doses on time/he is wanting to receive his third dose today; No additional adverse events reported; This spontaneous report was received from a pharmacist referring to a male patient of unknown age. Information regarding the patient's concurrent conditions, medical history, historical drugs and concomitant therapies was not provided.     The pharmacist informed that the patient initiated hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) series at age 21 and received the first two doses on time (per the patient's report) at 0.5 milliliter, intramuscularly for prophylaxis (lot number and expiration date were not reported). The reporter was unable to provide dates of administration as the patient received them elsewhere and he was wanting to receive his third dose at the time of reporting. No further information provided. No additional adverse events reported.
Redness, itchiness on day 7-8 Flu-like symptoms first 30 hours from when vaccine given
Swollen lymph node to left axilla with tenderness; fatigue started 12/24/2020
This case was reported by a consumer and described the occurrence of runny nose in a 36-year-old male subject who was vaccinated with FLULAVAL (GlaxoSmithKline). A physician or other health care professional has not verified this report. Concurrent medical conditions included seasonal allergy. Concurrent medications included PPD. On 10 September 2012 at approximately 1700, the subject received unspecified dose of FLULAVAL (unknown, right arm). On 12 September 2012, 2 days after vaccination with FLULAVAL, the subject experienced runny nose, sniffles and influenza. The subject consulted his physician who told him "that what he was experiencing was not from the vaccine since the virus in there is dead". At the time of reporting the Runny nose, sniffles and flu were worse.
Experienced increased tinnitus after my first vaccine but much greater tinnitus after 2nd injection. Volume of my mild  tinnitus increased 3-4 times in intensity. It is now 3 weeks, 4 days post vaccine and symptoms still present.
Pt recv vax on 3/23/99; on 3/24/99 pt exp nausea, back pain to ribs & abdomen, fever (103), vomiting, U.R.I. sx
This spontaneous report as received from a healthcare worker refers to a 15 year old patient of unknown gender. There was no information about the patient's concomitant medications and pertinent medical history reported. On 25-JUN-2015, the patient was vaccinated with an improperly stored dose of GARDASIL (lot# K023432, expiration date 18-JUN-2016) (strength, dose, route and site of administration were not provided). No adverse effects were reported. This is one of several reports from the same reporter. Additional information has been requested.
Dizziness- occurred about 30 minutes after vaccination administration and went away within an hour Chills- went away within 24 hours of vaccine administration Raised bump- applied warm compress/heating pad initially to injection site and went away within 72 hours Sore arm- applied warm compress/heating pad initially to injection site and went away within 72 hours Low grade fever- went away within 24 hours of vaccine administration
Chills,dizziness,nausea, funny feeling in chest. Lasted for 2 days.
24 hrs after MENACTRA was given area in Left arm was red, swollen and warm. Overnight blistering developed in the central portion of the red area. The blistering area is about 1 in round surrounded by tiny little satellite blistering. The red and induration area is about 4-1/2 inches round.
Within about 3+ hours after receiving the second shot, I began to experience extreme thirst, foggy headed feelings and slight nausea; Within about 3+ hours after receiving the second shot, I began to experience extreme thirst, foggy headed feelings and slight nausea; Within about 3+ hours after receiving the second shot, I began to experience extreme thirst, foggy headed feelings and slight nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 10Mar2021 at 12:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included weak immune system in the past and asthma as a teenager that he outgrew. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 16Feb2021 at 13:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation and had no side effects. On 10Mar2021 at 04:30, within about 3 plus hours after receiving the second shot, the patient began to experience extreme thirst, foggy headed feelings and slight nausea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events within about 3 plus hours after receiving the second shot, he began to experience extreme thirst, foggy headed feelings and slight nausea was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.  .
This patient began experiencing itching and raised areas on her face, neck, back, and trunk of body on 01/16/01. Raised areas are erythemic and "splotchy" in appearance. Areas are fading at the present. The patient has not discussed with her MD. Denied any new foods, changes in behavior, and changes in medications. She planned to discuss with her MD. Denies any  problems with initially from the vaccine. Immunization site no evidence of erythema, edema, extreme, irritation or other problems.
This spontaneous report was received from a licensed practical nurse regarding a patient of unknown age and gender with no pertinent medical history reported. On 29-MAY-2013 the patient was vaccinated with the first dose of PROQUAD (Merck) (lot number and expiration date not reported) (0.5ml, route not reported). Other suspect therapies included VARIVAX (Merck) (lot number and expiration date not reported) (0.5ml, route not reported). No concomitant therapies were reported. The licensed practical nurse reported that the patient was administered a dose of both VARIVAX (Merck) and PROQUAD (Merck). The patient had not received any varicella vaccinations prior to 29-MAY-2013. No adverse effect reported. Additional information has been requested.
Arm pain 2 days Headache and muscle aches off and on for 7 days Tired for 5 days
Patient came in complaining of back pain, stomach cramping and constipation starting day after vaccine. Also arm at injection site was warm/red with a rash. Advised patient to take OTC remedies to help with symptoms, but patient stated she was sensitive to those medications and did not want to try them. Advised to watch for worsening symptoms in next few days, if so advised to seek medical help.
Sore left arm, also felt like I had a fever of 101 deg but was actually normal.  Headache and body aches
From initial information received on 01/28/04 from another manufacturer ( case number A0442068A) regarding an adverse event occurring in the USA, it was initially reported by a health care professional that a 25 year old female patient received Menomune A/C/Y/W-135, lot number not reported, administered in the left arm; Typhim VI, lot number not reported, administered in the right arm; Influenza Vaccine, lot number not reported, manufacturer unknown, administered in the left arm; a first dose of Engerix B, lot number ENG5460A (lot number incomplete), manufacturer GlaxoSmithKline, administered in the right are; all on 11/28/03. Later taht evening th patient developed a headache, low grade fever and achiness. The following day, on 11/29/03, the patient developed hives and itching on her torso and other parts of her body. On 11/30/03, the patient developed a swollen lymph node (site not reported), and a raised wheal at the injection site of her left arm. As of 12/03/03, the hives and itching have improved. The patient's recovery status was not reported.
This morning, patient experienced dime size rash on chest, no pain, non-pruritic rash Recommended primary provider if symptoms worsen
Approximately 1-2 minutes after vaccination she felt a "fullness" in her throat, Felt "woozy" and "altered".  given 25mg Benedryl with lessening of symptoms.
COVID side effects; I am having issues; COVID side effects; I am having issues; This is a spontaneous report from a contactable consumer (patient reported for self). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: unknown and Expiration date: unknown) via an unspecified route of administration, on an unspecified date as dose number unknown, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced COVID side effects; patient was having issues. Reporter stated that it was because of COVID, COVID side effects, patient was having issues and there was nobody to talk to. So, the patient wanted to speak to a supervisor. The outcome of the events was unknown.  The lot number for the vaccine, (BNT162B2), was not provided and will be requested during follow up.
intermit shivers, durations, "seconds" approx. #7 episodes  daily X 3 days. No other symptoms reported. No treatment required.
Experienced palpitations for half a month.; This spontaneous case was reported by a patient and describes the occurrence of PALPITATIONS (Experienced palpitations for half a month.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PALPITATIONS (Experienced palpitations for half a month.). At the time of the report, PALPITATIONS (Experienced palpitations for half a month.) had resolved.            No concomitant product use was reported.  The patient took 2 booster doses of Moderna and patient was not happy with it because patient experienced palpitations for half a month. The patient was informed that Moderna caused heart inflammation 4 times more likely. The patient wanted to know if Pfizer BionTech Covid-19 Bivalent Vaccine would cause inflammation of the heart/brain paralysis less likely than with Moderna Covid-19 Vaccine.  No treatment information was provided.
pain to the left side and all the way down to the left ankle; Pain to Left Side; This case was reported by a pharmacist via call center representative and described the occurrence of pain ankle in a 74-year-old female patient who received Herpes zoster (Shingrix) (batch number MT7C9, expiry date 15th April 2022) for prophylaxis.   On 8th July 2020, the patient received the 1st dose of Shingrix .5 ml. In July 2020, less than a week after receiving Shingrix, the patient experienced pain ankle and pain localized. On an unknown date, the outcome of the pain ankle and pain localized were not recovered/not resolved.   It was unknown if the reporter considered the pain ankle and pain localized to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and complained of pain to the left side and all the way down to the left ankle and the caller wanted to know if this pain was common.   Read from Shingrix PI in content and other content information on Shingrix.   The reporter did not consent to follow up.
Given vaccine on Dec 28th, Approx 2 hrs afterwards felt very tired. (feels same after flu shot). Then on the 29th was nauseated and vomited X 2. On Jan 1st was feeling better, but got up to walk and felt dizziness, nausea and vomiting continues. Can keep down liquids, but unable to eat anything.
Redness and swelling at injection site,  muscle pain, body aches, shivering, nausea, chills.  Started about 8 hours after vaccine and lasted about 12 hours
9/13/02 pt was brought by mother with R arm swelling. MD examined pt and dx cellulitis R upper extended arm. Rocephin 500mg IM inj given. Antibiotic by mouth and Benadryl given on 9/14/02. Mother brought child again c/o R A pain. Pt was referred to ER.
Vaccine administered after after 4 temperature excursions; Vaccine administered after after 4 temperature excursions; No aderse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions) and NO ADVERSE EVENT (No aderse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.  On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions) and NO ADVERSE EVENT (No aderse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions) and NO ADVERSE EVENT (No aderse event) outcome was unknown.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No aderse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions).    Concomitant product use was not provided by the reporter.  It was unknown if patient receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  It was reported that vaccine was moved from freezer to refrigerator on 12-Feb-2022. Of the ten vials in question 43 injections were given and 7 doses were wasted. Vaccine administered after 4 temperature excursions.  Treatment information was not provided.  This case contains information for the 15th of 43 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-689222 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-689222:Master case